Posted on February 11, 2009 by Sitemaster
Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper just published on line in Lancet Oncology aimed to assess the value of circulating tumor cell (CTC) counts as a prognostic factor for survival. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: circulating tumor cells, clinical trials, CTC, surrogate endpoint | Leave a comment »
Posted on October 28, 2008 by Sitemaster
Many reader will already have seen or heard reports of the demise of the SELECT prostate cancer prevention trial. In other news today:
- There is a recent review of trials of diet and dietary supplements
- Further evidence supports the potential of surrogate markers for prostate cancer mortality
- Saturation biopsies appear to overestimate the risk of prostate cancer … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: biopsy, diet, supplements, surrogate endpoint | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 